Russell Investments Group
EDIT icon

Russell Investments Group’s Editas Medicine EDIT Stock Holding History

Russell Investments Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$486K Buy
149,864
+8,782
+6% +$25.7K ﹤0.01% 2799
2026
Q1 		$348K Buy
141,082
+45,576
+48% +$96.4K ﹤0.01% 2643
2025
Q4 		$196K Buy
95,506
+16,938
+22% +$48.9K ﹤0.01% 2851
2025
Q3 		$273K Buy
78,568
+74,042
+1,636% +$207K ﹤0.01% 2695
2025
Q2 		$9.96K Sell
4,526
-5,779
-56% -$9.46K ﹤0.01% 3335
2025
Q1 		$12K Sell
10,305
-37,403
-78% -$55K ﹤0.01% 3211
2024
Q4 		$60.6K Sell
47,708
-3,453
-7% -$8.8K ﹤0.01% 2783
2024
Q3 		$174K Sell
51,161
-6,458
-11% -$28.1K ﹤0.01% 2540
2024
Q2 		$269K Buy
57,619
+44,781
+349% +$253K ﹤0.01% 2401
2024
Q1 		$95.3K Buy
12,838
+7,648
+147% +$63.5K ﹤0.01% 2580
2023
Q4 		$52.6K Buy
5,190
+4,156
+402% +$36.5K ﹤0.01% 2634
2023
Q3 		$8.06K Sell
1,034
-1,353
-57% -$11.6K ﹤0.01% 3057
2023
Q2 		$19.6K Sell
2,387
-94
-4% -$819 ﹤0.01% 2843
2023
Q1 		$18K Sell
2,481
-11,864
-83% -$105K ﹤0.01% 2827
2022
Q4 		$127K Sell
14,345
-23,953
-63% -$263K ﹤0.01% 2631
2022
Q3 		$466K Buy
38,298
+35,580
+1,309% +$554K ﹤0.01% 2273
2022
Q2 		$32K Buy
+2,718
New +$36.4K ﹤0.01% 2759
2022
Q1 		– Sell
-17,627
Closed -$466K – 2797
2021
Q4 		$466K Sell
17,627
-17,804
-50% -$613K ﹤0.01% 2471
2021
Q3 		$1.45M Buy
35,431
+13,614
+62% +$746K ﹤0.01% 2012
2021
Q2 		$1.23M Sell
21,817
-25,831
-54% -$954K ﹤0.01% 2207
2021
Q1 		$2M Sell
47,648
-9,088
-16% -$518K ﹤0.01% 1874
2020
Q4 		$3.98M Sell
56,736
-54,562
-49% -$2.24M 0.01% 1365
2020
Q3 		$3.12M Sell
111,298
-2,894
-3% -$94.3K 0.01% 1411
2020
Q2 		$3.38M Buy
114,192
+70,288
+160% +$1.84M 0.01% 1328
2020
Q1 		$870K Buy
+43,904
New +$1.11M ﹤0.01% 1912
2018
Q1 		– Sell
-102,075
Closed -$3.2M – 2929
2017
Q4 		$3.2M Buy
+102,075
New +$2.57M 0.01% 1579
2017
Q1 		– Sell
-17,647
Closed -$284K – 3009
2016
Q4 		$284K Buy
+17,647
New +$268K ﹤0.01% 2633

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Russell Investments Group's EDIT Position: Q2 2026 in Review

Russell Investments Group increased its Editas Medicine (EDIT) stake by 6.2% in Q2 2026, buying an estimated $25.7K and bringing the position to 149,864 shares worth $486K. The position accounts for ﹤0.01% of the portfolio, ranked #2799.

Russell Investments Group first reported a position in EDIT in Q4 2016 and has held it in 27 quarters since. The position peaked at $3.98M in Q4 2020. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Russell Investments Group held 149,864 shares of Editas Medicine worth $486K as of Q2 2026.
  • Russell Investments Group bought 8,782 Editas Medicine shares in Q2 2026, an estimated $25.7K.
  • Editas Medicine made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2799 holding.
  • Russell Investments Group first reported a position in Editas Medicine in Q4 2016 and has held it in 27 quarters since.
  • Russell Investments Group's Editas Medicine position peaked at $3.98M in Q4 2020.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.